Literature DB >> 15505853

Drug-eluting stents for coronary bifurcations: insights into the crush technique.

John A Ormiston1, Erin Currie, Mark W I Webster, Patrick Kay, Peter N Ruygrok, James T Stewart, Richard C Padgett, Monique J Panther.   

Abstract

Sirolimus-eluting stents appear to reduce substantially restenosis following percutaneous coronary bifurcation intervention. The crush technique was devised to reduce restenosis further by improving stent and drug application to the side-branch ostium. We aimed to investigate the performance of drug-eluting stent (DES) platforms with the crush technique, to identify deployment pitfalls, and to clarify the best deployment strategies. Each stage of the crush technique was photographed in a bifurcation phantom. Simultaneous side- and main-branch dilatation (kissing balloons) fully expanded the stent in the side-branch ostium, widened the gaps between stent struts covering the side branch, and eliminated main-branch distortion. With side branches angled at > 70 degrees , sequential (side- then main-branch) inflations may be needed to achieve best results. Postdilatation of the main branch with a balloon of narrower diameter than the deploying balloon caused main-branch stent distortion. These principles applied to all the bifurcation strategies and stent designs tested.

Entities:  

Mesh:

Year:  2004        PMID: 15505853     DOI: 10.1002/ccd.20120

Source DB:  PubMed          Journal:  Catheter Cardiovasc Interv        ISSN: 1522-1946            Impact factor:   2.692


  13 in total

1.  Comparative endoluminal visualization of TAXUS crush-stenting at 9 months follow-up by intravascular ultrasound and optical coherence tomography.

Authors:  L Buellesfeld; V Lim; U Gerckens; R Mueller; E Grube
Journal:  Z Kardiol       Date:  2005-10

2.  Treatment of bifurcation lesions with two stents: one year angiographic and clinical follow up of crush versus T stenting.

Authors:  L Ge; I Iakovou; J Cosgrave; P Agostoni; F Airoldi; G M Sangiorgi; I Michev; A Chieffo; M Montorfano; M Carlino; N Corvaja; A Colombo
Journal:  Heart       Date:  2005-06-17       Impact factor: 5.994

3.  New strategies in the treatment of coronary bifurcations.

Authors:  I Iakovou; N Foin; A Andreou; N Viceconte; C Di Mario
Journal:  Herz       Date:  2011-05       Impact factor: 1.443

Review 4.  Dedicated bifurcation analysis: dedicated devices.

Authors:  Carlos Collet; Ricardo A Costa; Alexandre Abizaid
Journal:  Int J Cardiovasc Imaging       Date:  2011-03-17       Impact factor: 2.357

Review 5.  Percutaneous Coronary Intervention for Bifurcation: How Can We Outperform the Provisional Strategy?

Authors:  Andrew Kei-Yan Ng; Man-Hong Jim
Journal:  Clin Cardiol       Date:  2016-08-24       Impact factor: 2.882

6.  Coronary bifurcation stent morphology in dual-source CT: validation with micro-CT.

Authors:  Hye-Joung Eom; Dong Hyun Yang; Young-Hak Kim; Jae-Hyung Roh; Jihoon Kweon; Soo-Jin Kang; Namkug Kim; Joon-Won Kang; Tae-Hwan Lim
Journal:  Int J Cardiovasc Imaging       Date:  2016-08-09       Impact factor: 2.357

7.  Correction of Stent Distortion and Overhanging Stent Struts during Left Main Bifurcation Stenting by Selective Distal Stent Cell Re-Wiring: A Novel Guidewire Approach.

Authors:  Mahmoud Sabbah; Kazushige Kadota; Yasushi Fuku; Kazuaki Mitsudo
Journal:  Acta Cardiol Sin       Date:  2015-09       Impact factor: 2.672

8.  The Need For Dedicated Bifurcation Stents: A Critical Analysis.

Authors:  Maciej Lesiak
Journal:  Interv Cardiol       Date:  2016-10

Review 9.  Drug eluting stents: focus on Cypher sirolimus-eluting coronary stents in the treatment of patients with bifurcation lesions.

Authors:  Alaide Chieffo; Tiziana Claudia Aranzulla; Antonio Colombo
Journal:  Vasc Health Risk Manag       Date:  2007

10.  Study comparing the double kissing (DK) crush with classical crush for the treatment of coronary bifurcation lesions: the DKCRUSH-1 Bifurcation Study with drug-eluting stents.

Authors:  S L Chen; J J Zhang; F Ye; Y D Chen; T Patel; K Kawajiri; M Lee; T W Kwan; G Mintz; H C Tan
Journal:  Eur J Clin Invest       Date:  2008-06       Impact factor: 4.686

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.